An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
- Registration Number
- NCT00407095
- Lead Sponsor
- Solvay Pharmaceuticals
- Brief Summary
This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 140
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 Pardoprunox -
- Primary Outcome Measures
Name Time Method Safety: laboratory data, adverse events, vital signs, ECG 36 weeks
- Secondary Outcome Measures
Name Time Method On' and 'off' time recording, UPDRS parts 1-4, CGI-improvement, PDQ-39 total score: all change from baseline 36 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (87)
S308.3.007 Site # 220
🇺🇸LaJolla, California, United States
S308.3.007 Site # 211
🇺🇸San Francisco, California, United States
S308.3.007 Site # 214
🇺🇸Fort Lauderdale, Florida, United States
S308.3.007 Site # 218
🇺🇸Gainsville, Florida, United States
S308.3.007 Site # 213
🇺🇸Tampa, Florida, United States
S308.3.007 Site # 219
🇺🇸Augusta, Georgia, United States
S308.3.007 Site # 221
🇺🇸Chicago, Illinois, United States
S308.3.007 Site # 216
🇺🇸Kansas City, Kansas, United States
S308.3.007 Site # 224
🇺🇸Lexington, Kentucky, United States
S308.3.007 Site # 212
🇺🇸East Lansing, Michigan, United States
Scroll for more (77 remaining)S308.3.007 Site # 220🇺🇸LaJolla, California, United States